[go: up one dir, main page]

YU34196A - Peptides and compounds that bind to a receptor - Google Patents

Peptides and compounds that bind to a receptor

Info

Publication number
YU34196A
YU34196A YU34196A YU34196A YU34196A YU 34196 A YU34196 A YU 34196A YU 34196 A YU34196 A YU 34196A YU 34196 A YU34196 A YU 34196A YU 34196 A YU34196 A YU 34196A
Authority
YU
Yugoslavia
Prior art keywords
peptides
bind
receptor
compounds
peptide mimetics
Prior art date
Application number
YU34196A
Other languages
Serbo-Croatian (sh)
Inventor
Ronald Barrett
William Dower
Steven Cwirla
Sherril Johnson
Christian Gates
Nicholas Wrighton
David Duffin
Christopher Wagstrom
Peter Schatz
Larry Mattheakis
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of YU34196A publication Critical patent/YU34196A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Opisani su peptidni i peptidni mimetici koji se vezuju za i aktiviraju trombopoetinski receptor. Ovakvi peptidi i peptidni mimetici su korisni u metodama za lečenje hematoloških poremećaja a naročito, trombocitopenije kao posledice hemioterapije, radijacione terapije, ili transfuzija koštane srži kao i u dijagnostičkim metodama koje koriste obležene peptide i peptidne mimetike.Peptide and peptide mimetics that bind to and activate the thrombopoietin receptor have been described. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and in particular, thrombocytopenia as a consequence of chemotherapy, radiation therapy, or bone marrow transfusion as well as in diagnostic methods using coated peptides and peptide mimetics.

YU34196A 1995-06-07 1996-06-05 Peptides and compounds that bind to a receptor YU34196A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US48409095A 1995-06-07 1995-06-07
US47360495A 1995-06-07 1995-06-07
US47812895A 1995-06-07 1995-06-07
US47616895A 1995-06-07 1995-06-07
US47237195A 1995-06-07 1995-06-07
US48530195A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
YU34196A true YU34196A (en) 1999-03-04

Family

ID=27560032

Family Applications (1)

Application Number Title Priority Date Filing Date
YU34196A YU34196A (en) 1995-06-07 1996-06-05 Peptides and compounds that bind to a receptor

Country Status (5)

Country Link
AU (1) AU6046696A (en)
HR (1) HRP960256A2 (en)
MY (1) MY113497A (en)
WO (1) WO1996040189A1 (en)
YU (1) YU34196A (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
WO2000024770A2 (en) 1998-10-23 2000-05-04 Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
NZ511489A (en) * 1998-11-05 2003-08-29 Toyama Chemical Co Ltd A benzene derivative useful as an AP-1 inhibitor
AU1764200A (en) * 1998-12-18 2000-07-12 Mount Sinai Hospital Corporation Three dimensional structure of a sterile alpha motif domain
DK1141014T3 (en) 1999-01-06 2005-04-11 Genentech Inc Insulin-like growth factor (IGF) in mutant variant
WO2001010891A2 (en) * 1999-08-05 2001-02-15 Research Corporation Technologies, Inc. Il-16 antagonists
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
DE60136656D1 (en) * 2000-12-05 2009-01-02 Alexion Pharma Inc Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
JP2004532203A (en) * 2001-03-21 2004-10-21 ザ、ユニバーシティ、オブ、テキサス、システム Glycosaminoglycan inhibitors
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
BR0314591A (en) 2002-09-18 2005-08-09 Ortho Mcneil Pharm Inc Platelet augmentation methods and hematopoietic stem cell production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
BRPI0411172A (en) 2003-05-12 2006-07-18 Affymax Inc peptide, peptide dimer, its use and pharmaceutical composition
AP2042A (en) 2003-05-12 2009-09-07 Affymax Inc Novel peptides that bind to the erythropoietin receptor
BRPI0411166A (en) 2003-05-12 2006-07-18 Affymax Inc compound comprising a peptide moiety, a spacer moiety and a water soluble polymer moiety and a pharmaceutical composition comprising such a compound
WO2006062240A1 (en) 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
KR101215207B1 (en) 2004-12-14 2012-12-26 닛산 가가쿠 고교 가부시키 가이샤 Amide compound and thrombopoietin receptor activator
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
JP5104752B2 (en) 2005-07-20 2012-12-19 日産化学工業株式会社 Pyrazole compound and thrombopoietin receptor activator
JP5205967B2 (en) 2005-11-07 2013-06-05 日産化学工業株式会社 Hydrazide compounds and thrombopoietin receptor activators
JP5157900B2 (en) 2006-06-07 2013-03-06 日産化学工業株式会社 Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP1897888A1 (en) * 2006-09-05 2008-03-12 AplaGen GmbH Peptides binding the TPO receptor
WO2008028645A1 (en) * 2006-09-05 2008-03-13 Aplagen Gmbh Peptides binding the tpo receptor
WO2008095004A2 (en) 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8889732B2 (en) 2009-10-23 2014-11-18 Nissan Chemical Industries, Ltd. Fused heterocyclic compounds and thrombopoietin receptor activators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides

Also Published As

Publication number Publication date
MY113497A (en) 2002-03-30
AU6046696A (en) 1996-12-30
HRP960256A2 (en) 1998-02-28
WO1996040189A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
YU34196A (en) Peptides and compounds that bind to a receptor
MX9709315A (en) Peptides and compounds that bind to a thrombopoietin receptor.
TR200401638T2 (en) Peptides and compounds that bind to a receptor.
PT724456E (en) ANTIBODIES AGAINST CD4
ATE477273T1 (en) HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DE69738329D1 (en) TESTIMONIES OF ANTIGENES TO MHC CLASS I PROCESSING PATH THROUGH THE HELP OF ANTHRAXTOXIN FUSION PROTEIN
EP0687183A4 (en) Synergistic composition of cd4-based protein and anti-hiv-1 antibody, and methods of using same
EA200001041A1 (en) ANTIBODIES TO CD23, THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
ES2178000T3 (en) COMPOSITIONS AND METHODS TO TREAT INFECTIONS USING INDOLICIDINE ANALOGS.
EP1194164B8 (en) Prion protein peptides and uses thereof
EP0552296A4 (en) Mouse monoclonal antibodies
ATE396205T1 (en) THE USE OF PEPTIDES OF IL-2 AND PEPTIDE DERIVATIVES AS THERAPEUTIC AGENTS
ATE280777T1 (en) BRADYKININ ANTAGONIST PEPTIDES WITH N-SUBSTITUTED GLYCINES
ATE69727T1 (en) COMPOSITION FOR THE TREATMENT OF PATIENTS SUFFERING FROM HAEMOPHILIA-A INHIBITOR.
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
ATE251886T1 (en) USE OF APOE TO BIND TAU AND MAP2C PROTEINS AND TREAT ALZHEIMER'S DISEASE
EA200001127A1 (en) BACTERIAL FEROMONS AND THEIR USE
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE
DE69409961D1 (en) TRIARYLETHYLENE DERIVATIVES FOR THERAPEUTIC USE
ES2122912A1 (en) Metalocarboxypeptidase inhibitors and derived molecules used as antitumor agents
DE59610098D1 (en) PROTEIN WITH ANTI-TUMOR EFFECT
DE59611353D1 (en) TRANSKETOLASE-RELATED PROTEIN
RU94026276A (en) Receptors of interleukin-12 and antibodies